TY - JOUR
T1 - Confirmation of thermal dose as a predictor of local control in cervical carcinoma patients treated with state-of-the-art radiation therapy and hyperthermia
AU - Kroesen, Michiel
AU - Mulder, Hendrik T.
AU - van Holthe, Jeanette M.L.
AU - Aangeenbrug, Aleida A.
AU - Mens, Jan Willem M.
AU - van Doorn, Helena C.
AU - Paulides, Margarethus M.
AU - Oomen-de Hoop, Esther
AU - Vernhout, Rene M.
AU - Lutgens, Ludy C.
AU - van Rhoon, Gerard C.
AU - Franckena, Martine
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Background: Addition of deep hyperthermia results in improved local control (LC) and overall survival (OS) compared to radiotherapy alone in patients with cervical carcinoma. Previously, we showed that the thermal dose of hyperthermia significantly correlates with LC and disease specific survival (DSS). Over the last decade, new radiation techniques were introduced resulting in improved LC. Aim: To validate the effect of thermal dose in a more recent cohort of patients treated with modern radiotherapy techniques, including image guided brachytherapy (IGBT). Methods: We analyzed primary cervical carcinoma patients treated with a combination of radiotherapy and deep hyperthermia between 2005 and 2016 at our institute. Data on patient, tumor and treatment were collected including the thermal dose parameters TRISE and CEM43T90. Follow-up data on LC, disease free survival, DSS, OS as well as late toxicity data were collected. Data were analyzed using the Cox proportional hazard and Kaplan–Meier analyses. Results: 227 patients were included. In multivariate analysis, histology, FIGO stage, lymphadenopathy, TRISE, CEM43T90 and IGBT had a significant effect on LC. In the patients treated with IGBT, the thermal dose parameter TRISE remained to have a significant effect on LC in univariate analysis. Conclusions: The positive association between thermal dose and clinical outcome is replicated in an independent, recent cohort of cervical carcinoma patients. Importantly, in patients receiving IGBT, the effect of thermal dose on clinical outcome is still observed.
AB - Background: Addition of deep hyperthermia results in improved local control (LC) and overall survival (OS) compared to radiotherapy alone in patients with cervical carcinoma. Previously, we showed that the thermal dose of hyperthermia significantly correlates with LC and disease specific survival (DSS). Over the last decade, new radiation techniques were introduced resulting in improved LC. Aim: To validate the effect of thermal dose in a more recent cohort of patients treated with modern radiotherapy techniques, including image guided brachytherapy (IGBT). Methods: We analyzed primary cervical carcinoma patients treated with a combination of radiotherapy and deep hyperthermia between 2005 and 2016 at our institute. Data on patient, tumor and treatment were collected including the thermal dose parameters TRISE and CEM43T90. Follow-up data on LC, disease free survival, DSS, OS as well as late toxicity data were collected. Data were analyzed using the Cox proportional hazard and Kaplan–Meier analyses. Results: 227 patients were included. In multivariate analysis, histology, FIGO stage, lymphadenopathy, TRISE, CEM43T90 and IGBT had a significant effect on LC. In the patients treated with IGBT, the thermal dose parameter TRISE remained to have a significant effect on LC in univariate analysis. Conclusions: The positive association between thermal dose and clinical outcome is replicated in an independent, recent cohort of cervical carcinoma patients. Importantly, in patients receiving IGBT, the effect of thermal dose on clinical outcome is still observed.
KW - CEM43T90
KW - Cervical cancer
KW - Hyperthermia
KW - Image guided brachytherapy
KW - Thermal dose
KW - Treatment outcome
KW - Trise
UR - http://www.scopus.com/inward/record.url?scp=85068583605&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2019.06.021
DO - 10.1016/j.radonc.2019.06.021
M3 - Article
C2 - 31302345
AN - SCOPUS:85068583605
SN - 0167-8140
VL - 140
SP - 150
EP - 158
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
ER -